The Conversation (0)
M Pharmaceutical's Trimeo Patent Allowed by Canadian Intellectual Property Office
Nov. 17, 2015 11:00AM PST
Pharmaceutical Investing
M Pharmaceutical Inc. (CSE:MQ) announced the Canadian Intellectual Property Office has allowed M Pharmaceutical Inc.’s patent application 2,720,691, entitled “Bezoar-Forming Units for Weight Control,” to be issued.
M Pharmaceutical Inc. (CSE:MQ) announced the Canadian Intellectual Property Office has allowed M Pharmaceutical Inc.’s patent application 2,720,691, entitled “Bezoar-Forming Units for Weight Control,” to be issued. This patent was filed on April 28, 2009, and will remain in force for 20 years from that date.
The patent claims cover the design, composition, and methods to use bezoar-forming units that are temporary and dissolvable. This patent is fundamental to the design of M Pharma’s Trimeo capsules, currently under development for weight loss.
M Pharmaceutical CEO, Matthew Lehman, stated:
I am pleased to report that this patent will be issued in Canada. It is a key part of our intellectual property strategy to protect our investment in developing Trimeo for weight-loss applications in major global markets.
Connect with M Pharmaceutical Inc. (CSE:MQ) to receive an Investor Kit.